We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Altimmune Inc | NASDAQ:ALT | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.5399 | 7.54% | 7.6999 | 7.10 | 8.50 | 8.0751 | 7.17 | 7.22 | 4,552,417 | 05:00:03 |
From May 2023 to May 2024
By Colin Kellaher
Altimmune has won U.S. Food and Drug Administration fast-track designation for its lead product candidate pemvidutide in the treatment of nonalcoholic steatohepatitis, the chronic liver condition commonly known as NASH.
The Gaithersburg, Md., clinical-stage biopharmaceutical company on Thursday said it is studying the efficacy and safety of pemvidutide in NASH in a Phase 2b placebo-controlled biopsy-driven trial.
The FDA's fast-track program is designed to facilitate the development and expedite the review of treatments for serious or potentially life-threatening illnesses with high unmet medical needs.
There are currently no FDA-approved drugs to treat NASH, which is caused by a buildup of fat in the liver and is estimated to affect 17 million Americans.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 26, 2023 08:00 ET (12:00 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Altimmune Chart |
1 Month Altimmune Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
